Medicine

Insulin Patch Pumps Market Size Worth $1.7 Billion by 2027 | CAGR: 10.9%: Grand View Research, Inc.

Thursday, April 2, 2020 - 9:05am

SAN FRANCISCO, April 2, 2020 /PRNewswire/ -- The global insulin patch pumps market size is expected to reach USD 1.7 Billionby 2027, according to a new report by Grand View Research, Inc., exhibiting a CAGRof 10.9%over the forecast period.

Key Points: 
  • SAN FRANCISCO, April 2, 2020 /PRNewswire/ -- The global insulin patch pumps market size is expected to reach USD 1.7 Billionby 2027, according to a new report by Grand View Research, Inc., exhibiting a CAGRof 10.9%over the forecast period.
  • Moreover, technological advancements and several product launches in the field of insulin patch pumps are further augmenting growth.
  • In addition, they are more affordable than conventional insulin pumps and are rapidly capturing a significant share of the insulin patch pumps market.
  • For instance, in March 2019, a South Korean Company-EoFlow-received FDA approval for its newly designed patch pump-EoPatch in the U.S.
    Grand View Research has segmented the global insulin patch pumps market based on delivery mode, product type, distribution channel, and region:
    Insulin Patch Pumps Delivery Mode Outlook (Volume Units; Revenue USD Million, 2016 - 2027)

Insulin Patch Pumps Market Size Worth $1.7 Billion by 2027 | CAGR: 10.9%: Grand View Research, Inc.

Thursday, April 2, 2020 - 9:05am

SAN FRANCISCO, April 2, 2020 /PRNewswire/ -- The global insulin patch pumps market size is expected to reach USD 1.7 Billionby 2027, according to a new report by Grand View Research, Inc., exhibiting a CAGRof 10.9%over the forecast period.

Key Points: 
  • SAN FRANCISCO, April 2, 2020 /PRNewswire/ -- The global insulin patch pumps market size is expected to reach USD 1.7 Billionby 2027, according to a new report by Grand View Research, Inc., exhibiting a CAGRof 10.9%over the forecast period.
  • Moreover, technological advancements and several product launches in the field of insulin patch pumps are further augmenting growth.
  • In addition, they are more affordable than conventional insulin pumps and are rapidly capturing a significant share of the insulin patch pumps market.
  • For instance, in March 2019, a South Korean Company-EoFlow-received FDA approval for its newly designed patch pump-EoPatch in the U.S.
    Grand View Research has segmented the global insulin patch pumps market based on delivery mode, product type, distribution channel, and region:
    Insulin Patch Pumps Delivery Mode Outlook (Volume Units; Revenue USD Million, 2016 - 2027)

Actimed Therapeutics Appoints Annalisa Jenkins as Advisor

Thursday, April 2, 2020 - 9:00am

LONDON, April 2, 2020 /PRNewswire/ -- Actimed Therapeutics, the clinical stage company focused on bringing innovation to the treatment of muscle wasting disorders, with a focus on cachexia, today announces the appointment of Dr Annalisa Jenkins, M.B.B.S., F.R.C.P.

Key Points: 
  • LONDON, April 2, 2020 /PRNewswire/ -- Actimed Therapeutics, the clinical stage company focused on bringing innovation to the treatment of muscle wasting disorders, with a focus on cachexia, today announces the appointment of Dr Annalisa Jenkins, M.B.B.S., F.R.C.P.
  • Robin Bhattacherjee, CEO of Actimed Therapeutics, said: "We are delighted that Annalisa has agreed to become an Advisor to Actimed.
  • Dr Jenkins is a biopharma thought leader with over 25 years of industry experience.
  • Actimed is currently preparing for further clinical studies in cachexia in Non-Small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC).

Actimed Therapeutics Appoints Annalisa Jenkins as Advisor

Thursday, April 2, 2020 - 9:00am

LONDON, April 2, 2020 /PRNewswire/ -- Actimed Therapeutics, the clinical stage company focused on bringing innovation to the treatment of muscle wasting disorders, with a focus on cachexia, today announces the appointment of Dr Annalisa Jenkins, M.B.B.S., F.R.C.P.

Key Points: 
  • LONDON, April 2, 2020 /PRNewswire/ -- Actimed Therapeutics, the clinical stage company focused on bringing innovation to the treatment of muscle wasting disorders, with a focus on cachexia, today announces the appointment of Dr Annalisa Jenkins, M.B.B.S., F.R.C.P.
  • Robin Bhattacherjee, CEO of Actimed Therapeutics, said: "We are delighted that Annalisa has agreed to become an Advisor to Actimed.
  • Dr Jenkins is a biopharma thought leader with over 25 years of industry experience.
  • Actimed is currently preparing for further clinical studies in cachexia in Non-Small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC).

How to Implement Social Distancing Practices in Your Workplace

Thursday, April 2, 2020 - 8:00am

This quick guide showcases essential distancing supplies and illustrates steps to take to incorporate the concept of social distancing in your facility.

Key Points: 
  • This quick guide showcases essential distancing supplies and illustrates steps to take to incorporate the concept of social distancing in your facility.
  • Also known as "physical distancing," social distancing is the practice of staying six feet away from other people and avoiding person-to-person contact in order to prevent the spread of respiratory illness.
  • Wall signs that remind people to wash their hands and keep their distance are also great tools to encourage mindful social distancing.
  • Creative Safety Supply's downloadable quick guide shows you how you can implement social distancing in your business by providing helpful tools and steps.

Experts Talk About Hormone Replacement Therapies On "In Depth" With Laurence Fishburne

Thursday, April 2, 2020 - 8:00am

An impending episode will shift to the world of medicine and will interview medical professionals about hormone replacement therapies.

Key Points: 
  • An impending episode will shift to the world of medicine and will interview medical professionals about hormone replacement therapies.
  • Hormone replacement therapy (HRT) is a development in medicine that has been aiding women for several decades.
  • The show will provide more education about available hormone replacement therapies in the new episode of "In Depth" with Laurence Fishburne.
  • The educative television program "In Depth" with host Laurence Fishburne is given careful inspection before broadcast.

NOXXON Announces Completion of Patient Recruitment for the First Dose Cohort in the Phase 1/2 Brain Cancer Study Of NOX-A12 Plus Radiotherapy

Thursday, April 2, 2020 - 7:00am

The study investigates three dose regimens of NOX-A12 (200, 400 and 600 mg/week), each combined with external-beam radiotherapy in newly diagnosed brain cancer patients in a Phase 1/2 clinical trial.

Key Points: 
  • The study investigates three dose regimens of NOX-A12 (200, 400 and 600 mg/week), each combined with external-beam radiotherapy in newly diagnosed brain cancer patients in a Phase 1/2 clinical trial.
  • Under the approved protocol, it is planned that each patient is treated with NOX-A12 for up to six months.
  • The combination of NOX-A12 and radiotherapy has so far been well-tolerated by the patients that participated in this clinical trial.
  • In September 2019 the company initiated an additional trial with NOX-A12 in brain cancer in combination with radiotherapy.

AAGL to Host LIVE Webinar on Safe Gynecologic Surgery During the COVID-19 Pandemic

Thursday, April 2, 2020 - 6:00am

"This webinar is slated to be an engaging and informative discussion from leading surgeons on the frontlines of the COVID pandemic."

Key Points: 
  • "This webinar is slated to be an engaging and informative discussion from leading surgeons on the frontlines of the COVID pandemic."
  • -Jubilee Brown, MD, AAGL President
    This webinar training will be available live on AAGL's Online Video Platform, SurgeryU.
  • AAGL is a professional medical association of laparoscopic surgeons and is the global leader in minimally invasive gynecologic surgery.
  • The AAGL is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Sensorion Reports Full-year 2019 Financial Results and Business Update

Thursday, April 2, 2020 - 6:30am

As part of this consortium, Sensorion will receive up to 5.6 million over the duration of the project contingent on milestones completion.

Key Points: 
  • As part of this consortium, Sensorion will receive up to 5.6 million over the duration of the project contingent on milestones completion.
  • SENS-111 (Seliforant) was safe and well tolerated in a Phase 2 proof-of-concept study for the treatment of acute unilateral vestibulopathy (AUV).
  • However, it did not meet the primary endpoint of vertigo intensity and Sensorion stopped all development activities for SENS-111.
  • On the 13th of March, Sensorion made an update on timelines for the ongoing Phase 2 study of SENS-401 to treat Sudden Sensorineural Hearing Loss (SSNHL).

Digital Health: Diabetes Apps and Virtual Coaching

Wednesday, April 1, 2020 - 10:21pm

This special technology-based report provides an overview of diabetes, wearable glucose monitoring devices,smartphone-based digital health technologies, and attempts to answer the question:can digital health help improve diabetes?

Key Points: 
  • This special technology-based report provides an overview of diabetes, wearable glucose monitoring devices,smartphone-based digital health technologies, and attempts to answer the question:can digital health help improve diabetes?
  • Smartphone-based digital health technologies are expected to transform the diabetes management market over the next decade by substantially improving diabetes outcomes and reducing healthcare costs.These technologies are engaging and empowering patients, improving glycemic control, and lowering complications.Digital health technologies are defined in this report as: diabetes smartphone apps integrated with blood glucose monitoring devices (both standard blood glucose meters and continuous glucose monitoring systems) and personalized virtual diabetes coaching services.
  • The adoption of smartphone-based digital health technologies for diabetes management is being driven by:
    positive clinical data supporting reduced complications and healthcare costs.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.